Quantcast
Home > Quotes > VKTX
VKTX

Viking Therapeutics, Inc. Common Stock (VKTX) Quote & Summary Data

$7.95
*  
0.06
0.75%
Get VKTX Alerts
*Delayed - data as of Jun. 24, 2019  -  Find a broker to begin trading VKTX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VKTX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
22.5
Today's High / Low
$ 8.13 / $ 7.90
Share Volume
1,495,593
50 Day Avg. Daily Volume
2,097,768
Previous Close
$ 8.01
52 Week High / Low
$ 24 / $ 6.97
Market Cap
572,778,873
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-1.48

Intraday Chart

Shares Traded

Share Volume:
1,495,593
50 Day Avg. Daily Volume:
2,097,768

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.38

Trading Range

The current last sale of $7.95 is 14.06% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.13 $ 24
 Low: $ 7.90 $ 6.97

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, or TRß. In September 2018, we announced top-line results from a 12-week, Phase 2 clinical trial of VK2809 in patients with non-alcoholic fatty liver disease, or NAFLD, and elevated low-density lipoprotein cholesterol, or LDL-C. The study successfully achieved its primary endpoint, with patients receiving VK2809 demonstrating statistically significant reductions in LDL-C compared with placebo. In addition, the trial's secondary endpoint was achieved, with VK2809-treated patients experiencing statistically significant reductions in liver fat content compared with placebo.  ... More ...  



Risk Grade

Where does VKTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 8
Open Date:
Jun. 24, 2019
Close Price:
$ 7.95
Close Date:
Jun. 24, 2019


Consensus Recommendation

Analyst Info